{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:35Z","timestamp":1786987535141,"version":"build-2736575974"},"reference-count":299,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160447"],"award-info":[{"award-number":["82160447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105278","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:51:17Z","timestamp":1773589877000},"page":"105278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Harnessing synergy: Innovative combinations to overcome PARP inhibitor resistance in cancer treatment"],"prefix":"10.1016","volume":"222","author":[{"given":"Yurun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-3756","authenticated-orcid":false,"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10398","key":"10.1016\/j.critrevonc.2026.105278_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s43018-022-00355-4","article-title":"MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis","volume":"3","author":"Alborzinia","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105278_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920974201","article-title":"XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib","volume":"12","author":"Ali","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jconrel.2024.11.061","article-title":"Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer","volume":"377","author":"Alradwan","year":"2025","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-10-1252","article-title":"CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors","volume":"71","author":"Anderson","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat. Commun."},{"issue":"53","key":"10.1016\/j.critrevonc.2026.105278_bib7","doi-asserted-by":"crossref","first-page":"55117","DOI":"10.1074\/jbc.M404524200","article-title":"Involvement of poly(ADP-ribose) polymerase-1 and XRCC1\/DNA ligase III in an alternative route for DNA double-strand breaks rejoining","volume":"279","author":"Audebert","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41580-022-00571-x","article-title":"Revolutionizing DNA repair research and cancer therapy with CRISPR-Cas screens","volume":"24","author":"Awwad","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105278_bib10","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105278_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179134","article-title":"Poltheta inhibitor (ART558) demonstrates a synthetic lethal effect with PARP and RAD52 inhibitors in glioblastoma cells","volume":"25","author":"Barszczewska-Pietraszek","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112538","article-title":"Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors","volume":"42","author":"Bhin","year":"2023","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7035","key":"10.1016\/j.critrevonc.2026.105278_bib15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib16","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2020.05.011","article-title":"DNA damage repair deficiency in prostate cancer","volume":"6","author":"Burdak-Rothkamm","year":"2020","journal-title":"Trends Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105278_bib17","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","article-title":"The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors","volume":"84","author":"Cadzow","year":"2024","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105278_bib18","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/jm020259n","article-title":"Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure","volume":"45","author":"Canan Koch","year":"2002","journal-title":"J. Med Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100585","article-title":"Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A\/MaNGO-OV2 trial","volume":"7","author":"Capoluongo","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic Lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"7538","key":"10.1016\/j.critrevonc.2026.105278_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib24","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/1078-0432.CCR-19-1570","article-title":"Significance of BRCA2 and RB1 Co-loss in aggressive prostate cancer progression","volume":"26","author":"Chakraborty","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cell.2024.01.015","article-title":"PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends","volume":"187","author":"Chappidi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105278_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216507","article-title":"Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma","volume":"582","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"issue":"8021","key":"10.1016\/j.critrevonc.2026.105278_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105278_bib28","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100744","article-title":"Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer","volume":"55","author":"Chiappa","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105278_bib31","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.molcel.2023.09.022","article-title":"The crosstalk between DNA repair and immune responses","volume":"83","author":"Cimprich","year":"2023","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105278_bib33","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"10106","key":"10.1016\/j.critrevonc.2026.105278_bib34","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500904X","article-title":"PARP inhibitors for cancer therapy","volume":"7","author":"Curtin","year":"2005","journal-title":"Expert Rev. Mol. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105278_bib41","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib42","first-page":"17","article-title":"Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic model","volume":"52","author":"DeJongh","year":"2025","journal-title":"J. Pharm. Pharm."},{"issue":"43","key":"10.1016\/j.critrevonc.2026.105278_bib43","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/s41388-021-02003-0","article-title":"A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors","volume":"40","author":"Di Giulio","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and gaps: controversies and future research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105278_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113580","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial","volume":"200","author":"Dieras","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"728","key":"10.1016\/j.critrevonc.2026.105278_bib47","doi-asserted-by":"crossref","first-page":"eadg7740","DOI":"10.1126\/scitranslmed.adg7740","article-title":"Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer","volume":"16","author":"Ding","year":"2024","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005627","article-title":"STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","volume":"11","author":"Ding","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib49","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/ijgc-2020-002073","article-title":"ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy","volume":"31","author":"Elyashiv","year":"2021","journal-title":"Int J. Gynecol. Cancer"},{"issue":"7035","key":"10.1016\/j.critrevonc.2026.105278_bib52","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105278_bib53","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","article-title":"100 years of the Warburg effect: a cancer metabolism endeavor","volume":"187","author":"Fendt","year":"2024","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib54","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-022-00513-x","article-title":"Targeting the gut microbiota for cancer therapy","volume":"22","author":"Fernandes","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaoncol.2020.7310","article-title":"Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial","volume":"7","author":"Filho","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib58","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1073\/pnas.1619809114","article-title":"Oxidative DNA damage is epigenetic by regulating gene transcription via base excision repair","volume":"114","author":"Fleming","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105278_bib59","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib60","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41467-024-46593-1","article-title":"Discovery of a small-molecule inhibitor that traps Poltheta on DNA and synergizes with PARP inhibitors","volume":"15","author":"Fried","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib61","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib62","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41422-021-00597-4","article-title":"Pre-ribosomal RNA reorganizes DNA damage repair factors in nucleus during meiotic prophase and DNA damage response","volume":"32","author":"Gai","year":"2022","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001643","article-title":"Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer","volume":"9","author":"Ghonim","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib64","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1535-7163.MCT-23-0890","article-title":"A novel dual ATM\/DNA-PK Inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors","volume":"23","author":"Gilmer","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib65","article-title":"Preclinical study of trastuzumab deruxtecan (T-Dxd; DS-8201a) in combination with DNA damage response pathway inhibitors in HER2-low\/Hormone receptor negative breast cancer patient-derived xenograft models [abstract]","volume":"83","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105278_bib66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonz\u00e1lez-Mart\u00edn","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105278_bib67","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib69","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib70","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105278_bib71","article-title":"Acute BRCAness induction and AR signaling blockage through CDK12\/7\/9 degradation enhances parp inhibitor sensitivity in prostate cancer","author":"Gui","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib72","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","article-title":"Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer","volume":"10","author":"Ha","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib73","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41467-019-09641-9","article-title":"Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks","volume":"10","author":"Ha","year":"2019","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105278_bib74","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1016\/j.molcel.2022.08.014","article-title":"Double-stranded DNA binding function of RAD51 in DNA protection and its regulation by BRCA2","volume":"82","author":"Halder","year":"2022","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","article-title":"OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab","volume":"166","author":"Hardesty","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib77","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib78","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-18-0277","article-title":"The ewing family of tumors relies on BCL-2 and BCL-X(L) to escape PARP inhibitor toxicity","volume":"25","author":"Heisey","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.471","article-title":"Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition","volume":"8","author":"Hou","year":"2017","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004943","article-title":"DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining","volume":"11","author":"Howard","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.critrevonc.2026.105278_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216676","article-title":"PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation","volume":"586","author":"Hu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105278_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154528","article-title":"Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway","volume":"108","author":"Hu","year":"2023","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105278_bib85","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1158\/0008-5472.CAN-23-2738","article-title":"FANCI inhibition induces PARP1 redistribution to enhance the efficacy of PARP inhibitors in breast cancer","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105278_bib86","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1021\/acs.jafc.1c01657","article-title":"Bavachinin induces G2\/M cell cycle arrest and apoptosis via the ATM\/ATR signaling pathway in human small cell lung cancer and shows an antitumor effect in the xenograft model","volume":"69","author":"Hung","year":"2021","journal-title":"J. Agric. Food Chem."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105278_bib87","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111671","article-title":"Necessities in the processing of DNA double strand breaks and their effects on genomic instability and cancer","volume":"11","author":"Iliakis","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7267","key":"10.1016\/j.critrevonc.2026.105278_bib89","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib90","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7150\/thno.67300","article-title":"Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy","volume":"12","author":"Ji","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib91","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1535-7163.MCT-22-0396","article-title":"Bepotastine sensitizes ovarian cancer to PARP inhibitors through suppressing NF-kappaB-triggered SASP in cancer-associated fibroblasts","volume":"22","author":"Jin","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib92","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/s41467-020-17455-3","article-title":"BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining","volume":"11","author":"Kamp","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114234","article-title":"A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells","volume":"43","author":"Kanev","year":"2024","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib94","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4062\/biomolther.2025.029","article-title":"Dual disruption of DNA repair by a novel CHK2 inhibitor, ART-446, and olaparib is a promising strategy for triple-negative breast cancer therapy","volume":"33","author":"Kang","year":"2025","journal-title":"Biomol. Ther. (Seoul. )"},{"issue":"492","key":"10.1016\/j.critrevonc.2026.105278_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib96","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib97","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2018.36.6_suppl.163","article-title":"A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population","volume":"36","author":"Karzai","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib98","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-025-01544-5","article-title":"TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer","author":"Kim","year":"2025","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib99","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib100","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/2159-8290.CD-22-1220","article-title":"The DNA damage response and inflammation in cancer","volume":"13","author":"Klapp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105278_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107862","article-title":"Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4)","volume":"226","author":"Kobayashi","year":"2021","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41392-024-01893-2","article-title":"Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts","volume":"9","author":"Kolesnichenko","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib103","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.20892\/j.issn.2095-3941.2021.0178","article-title":"BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair","volume":"19","author":"Kong","year":"2021","journal-title":"Cancer Biol. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib104","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"issue":"7970","key":"10.1016\/j.critrevonc.2026.105278_bib105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","article-title":"The complementarity of DDR, nucleic acids and anti-tumour immunity","volume":"619","author":"Kornepati","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib106","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"issue":"Pt 4","key":"10.1016\/j.critrevonc.2026.105278_bib107","article-title":"Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors","volume":"242","author":"Kozarich","year":"2025","journal-title":"Biochem Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041240","article-title":"Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals","volume":"15","author":"Ladriere","year":"2023","journal-title":"Pharmaceutics"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105278_bib109","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1158\/1078-0432.CCR-18-0401","article-title":"Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts","volume":"24","author":"Laird","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib110","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf7175","article-title":"Clinical PARP inhibitors allosterically induce PARP2 retention on DNA","volume":"9","author":"Langelier","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib111","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41467-018-03234-8","article-title":"NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains","volume":"9","author":"Langelier","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib112","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.devcel.2022.02.013","article-title":"Chk1 dynamics in G2 phase upon replication stress predict daughter cell outcome","volume":"57","author":"Lebrec","year":"2022","journal-title":"Dev. Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib113","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib114","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2016.348","article-title":"Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer","volume":"115","author":"Ledermann","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082054","article-title":"PARP inhibitor resistance mechanisms and implications for post-progression combination therapies","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105278_bib116","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1200\/JCO.24.00683","article-title":"Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib117","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1541-7786.MCR-25-0268","article-title":"DDR2 confers ferroptosis resistance to cancer-associated fibroblasts and attenuates PARPi sensitivity of ovarian tumor cells","volume":"23","author":"Lesage","year":"2025","journal-title":"Mol. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib118","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib119","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","article-title":"Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma","volume":"36","author":"Li","year":"2024","journal-title":"Cell Metab."},{"issue":"8036","key":"10.1016\/j.critrevonc.2026.105278_bib120","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41586-024-07992-y","article-title":"AARS1 and AARS2 sense L-lactate to regulate cGAS as global lysine lactyltransferases","volume":"634","author":"Li","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib121","first-page":"574","article-title":"VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1\/2 mutations (gBRCA1\/2m): A randomized phase III trial ESMO virtual plenary","volume":"35","author":"Li","year":"2024","journal-title":"ESMO Virtual Plenary Abstr."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"480","key":"10.1016\/j.critrevonc.2026.105278_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci. Signal"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib124","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","article-title":"An open-label, multicenter, single-arm, phase ii study of fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian cancer","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105278_bib125","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.21.01511","article-title":"Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib126","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib127","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1093\/nar\/gkae316","article-title":"DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair","volume":"52","author":"Li","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","article-title":"The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41698-021-00189-w","article-title":"PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Precis Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib131","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41571-020-0410-2","article-title":"Clinical development and potential of photothermal and photodynamic therapies for cancer","volume":"17","author":"Li","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105278_bib132","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib133","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s13346-024-01650-6","article-title":"PARP inhibitor boost the efficacy of photothermal therapy to TNBC through enhanced DNA damage and inhibited homologous recombination repair","volume":"15","author":"Li","year":"2025","journal-title":"Drug Deliv. Transl. Res"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105278_bib134","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib135","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41594-022-00881-w","article-title":"Human DNA-dependent protein kinase activation mechanism","volume":"30","author":"Liang","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7894","key":"10.1016\/j.critrevonc.2026.105278_bib136","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41586-021-04274-9","article-title":"Structural insights into inhibitor regulation of the DNA repair protein DNA-PKcs","volume":"601","author":"Liang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105278_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110475","article-title":"Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Poltheta inhibition","volume":"200","author":"Lin","year":"2024","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-024-02025-8","article-title":"PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105278_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101767","article-title":"A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: efficacy and safety results from the phase II, multi-center ANNIE study","volume":"54","author":"Liu","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib140","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib141","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib142","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105278_bib143","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib144","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib146","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib147","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin. Oncol. (R. Coll. Radio. )"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105278_bib148","doi-asserted-by":"crossref","first-page":"12915","DOI":"10.1021\/acsnano.3c05009","article-title":"Simultaneous delivery of dual inhibitors of DNA damage repair sensitizes pancreatic cancer response to irreversible electroporation","volume":"17","author":"Long","year":"2023","journal-title":"ACS Nano"},{"issue":"6330","key":"10.1016\/j.critrevonc.2026.105278_bib149","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105278_bib150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pharmthera.2018.03.006","article-title":"Double-barreled gun: combination of PARP inhibitor with conventional chemotherapy","volume":"188","author":"Lu","year":"2018","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib151","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1038\/s41467-022-32166-7","article-title":"Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection","volume":"13","author":"Luedeman","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib152","article-title":"Biomimetic targeted co-delivery system engineered from genomic insights for precision treatment of osteosarcoma","volume":"12","author":"Luo","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105278_bib153","article-title":"Situ formation of fibronectin-enriched protein corona on epigenetic nanocarrier for enhanced synthetic lethal therapy","volume":"11","author":"Luo","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib154","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s12276-022-00809-w","article-title":"PBK drives PARP inhibitor resistance through the TRIM37\/NFkappaB axis in ovarian cancer","volume":"54","author":"Ma","year":"2022","journal-title":"Exp. Mol. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib155","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual poltheta\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med Chem."},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105278_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202109609","article-title":"Biomimetic nanoerythrosome-coated aptamer-DNA tetrahedron\/maytansine conjugates: ph-responsive and targeted cytotoxicity for HER2-positive breast cancer","volume":"34","author":"Ma","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105278_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216608","article-title":"Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment","volume":"584","author":"Madorsky Rowdo","year":"2024","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib158","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.dnarep.2013.10.005","article-title":"The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining","volume":"12","author":"Mansour","year":"2013","journal-title":"DNA Repair (Amst. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib159","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrm3822","article-title":"Understanding nucleotide excision repair and its roles in cancer and ageing","volume":"15","author":"Marteijn","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib161","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2021.12.005","article-title":"EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion","volume":"185","author":"Marzio","year":"2022","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib162","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7538","key":"10.1016\/j.critrevonc.2026.105278_bib163","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Mateos-Gomez","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib164","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib165","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"issue":"7713","key":"10.1016\/j.critrevonc.2026.105278_bib166","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","article-title":"High speed of fork progression induces DNA replication stress and genomic instability","volume":"559","author":"Maya-Mendoza","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib167","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12951-024-02835-4","article-title":"Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication","volume":"22","author":"Mengyuan","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib168","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105278_bib169","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105278_bib170","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105278_bib171","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fonc.2013.00113","article-title":"DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy","volume":"3","author":"Mladenov","year":"2013","journal-title":"Front Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105278_bib172","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib173","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10459","key":"10.1016\/j.critrevonc.2026.105278_bib174","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"8082","key":"10.1016\/j.critrevonc.2026.105278_bib175","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41586-025-09414-z","article-title":"NASP modulates histone turnover to drive PARP inhibitor resistance","volume":"645","author":"Moser","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib176","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1541-7786.MCR-21-0302","article-title":"GAS6\/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and parp inhibition through increased DNA damage and enhanced replication stress","volume":"20","author":"Mullen","year":"2022","journal-title":"Mol. Cancer Res"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105278_bib177","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105278_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102119","article-title":"Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches","volume":"50","author":"Nakatsuka","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib179","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.029","article-title":"ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer","volume":"516","author":"Nam","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib180","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib181","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","article-title":"Results of a randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer","volume":"130","author":"Nicum","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib182","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib183","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"7716","key":"10.1016\/j.critrevonc.2026.105278_bib184","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105278_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216820","article-title":"CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in triple negative breast cancer","volume":"589","author":"Orhan","year":"2024","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib186","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031116","article-title":"Sesquiterpene lactones potentiate olaparib-induced DNA damage in p53 wildtype cancer cells","volume":"23","author":"Osborne","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib187","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib188","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(24)00674-0","article-title":"Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial","volume":"26","author":"Oza","year":"2025","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105278_bib189","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.molcel.2021.09.005","article-title":"Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1\/53BP1 double-deficient cells by exposing ssDNA gaps","volume":"81","author":"Paes Dias","year":"2021","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib190","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A phase I study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib191","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib192","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2021.11.002","article-title":"MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts","volume":"82","author":"Papadopoulos","year":"2022","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib193","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","article-title":"Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification","volume":"82","author":"Pellegrino","year":"2022","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib194","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000480","article-title":"Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?","volume":"4","author":"Pellegrino","year":"2019","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","article-title":"Homologous recombination repair deficiency and the immune response in breast cancer: a literature review","volume":"13","author":"Pellegrino","year":"2020","journal-title":"Transl. Oncol."},{"issue":"8007","key":"10.1016\/j.critrevonc.2026.105278_bib196","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105278_bib197","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib198","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib199","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib200","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2024.10.022","article-title":"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"192","author":"Powell","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib201","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/s41436-020-0830-5","article-title":"Diagnosing hereditary cancer predisposition in men with prostate cancer","volume":"22","author":"Pritzlaff","year":"2020","journal-title":"Genet Med"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105278_bib202","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-21-0748","article-title":"Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin\/paclitaxel for gBRCA advanced breast cancer (BROCADE3 crossover)","volume":"27","author":"Puhalla","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib203","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105278_bib204","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1158\/0008-5472.CAN-24-4751","article-title":"PCBP2 mediates olaparib resistance in breast cancer by inhibiting m6a methylation to stabilize PARP1 mRNA","volume":"85","author":"Qi","year":"2025","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105278_bib206","article-title":"Dissecting the distinct tumor microenvironments of HRD and HRP ovarian cancer: implications for targeted therapies to overcome PARPi resistance in HRD tumors and refractoriness in HRP tumors","volume":"11","author":"Qiu","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.critrevonc.2026.105278_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2023.104823","article-title":"PARP inhibitor olaparib induced differential protein expression in cervical cancer cells","volume":"275","author":"Rajawat","year":"2023","journal-title":"J. Proteom."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13059-025-03528-3","article-title":"The histone acetyltransferase CBP participates in regulating the DNA damage response through ATM after double-strand breaks","volume":"26","author":"Ramadan","year":"2025","journal-title":"Genome Biol."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105278_bib209","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.20.03318","article-title":"Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study","volume":"39","author":"Ramalingam","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.33885","article-title":"JASPER: phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer","volume":"128","author":"Ramalingam","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib211","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/0008-5472.CAN-23-4129","article-title":"AKTing on R loops makes for an ATRactive target in ovarian cancer therapy","volume":"84","author":"Ramanarayanan","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib212","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41467-025-57257-z","article-title":"PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer","volume":"16","author":"Ran","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib213","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00412-017-0658-1","article-title":"Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes","volume":"127","author":"Ranjha","year":"2018","journal-title":"Chromosoma"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib214","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-o6-methylguanine-DNA methyltransferase expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"37","key":"10.1016\/j.critrevonc.2026.105278_bib215","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1038\/s41388-023-02785-5","article-title":"PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction","volume":"42","author":"Ray","year":"2023","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105278_bib216","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib217","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105278_bib218","doi-asserted-by":"crossref","first-page":"15557","DOI":"10.1021\/acs.jmedchem.4c01184","article-title":"Structural and biochemical insights into the mechanism of action of the clinical USP1 inhibitor, KSQ-4279","volume":"67","author":"Rennie","year":"2024","journal-title":"J. Med Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib219","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102231","article-title":"CDK4\/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer","volume":"52","author":"Roggero","year":"2025","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib222","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/s41467-023-42736-y","article-title":"Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4\/6 inhibitors in treatment-refractory ER+ breast cancer","volume":"14","author":"Saatci","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib223","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab plus talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib224","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib225","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34148-1","article-title":"Structural dynamics of DNA strand break sensing by PARP-1 at a single-molecule level","volume":"13","author":"Sefer","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib226","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4143\/crt.2021.473","article-title":"Inhibition of WEE1 potentiates sensitivity to PARP inhibitor in biliary tract cancer","volume":"54","author":"Seo","year":"2022","journal-title":"Cancer Res Treat."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105278_bib227","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","article-title":"Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance","volume":"28","author":"Serra","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib228","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1038\/s41467-022-34523-y","article-title":"Analysis of matched primary and recurrent BRCA1\/2 mutation-associated tumors identifies recurrence-specific drivers","volume":"13","author":"Shah","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105278_bib229","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib230","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1038\/s41467-019-13641-0","article-title":"PARP1 exhibits enhanced association and catalytic efficiency with gammaH2A.X-nucleosome","volume":"10","author":"Sharma","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105278_bib231","article-title":"Radiotherapy and olaparib in combination for carcinoma of the oesophagus: a phase I study","volume":"40","author":"Sheikh","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215919","article-title":"PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer","volume":"550","author":"Shen","year":"2022","journal-title":"Cancer Lett."},{"issue":"17-18","key":"10.1016\/j.critrevonc.2026.105278_bib233","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1101\/gad.348479.121","article-title":"The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells","volume":"35","author":"Simoneau","year":"2021","journal-title":"Genes Dev."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105278_bib234","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/JCO.2024.42.16_suppl.5510","article-title":"Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)","volume":"42","author":"Simpkins","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.annonc.2020.10.475","article-title":"Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial","volume":"32","author":"Sipos","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5-6","key":"10.1016\/j.critrevonc.2026.105278_bib236","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib237","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib238","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.molcel.2025.01.004","article-title":"A PARP2 active site helix melts to permit DNA damage-induced enzymatic activation","volume":"85","author":"Smith-Pillet","year":"2025","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib239","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1093\/nar\/gkac073","article-title":"RAD51 protects against nonconservative DNA double-strand break repair through a nonenzymatic function","volume":"50","author":"So","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib240","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41418-023-01118-z","article-title":"The regulation loop of MARVELD1 interacting with PARP1 in DNA damage response maintains genome stability and promotes therapy resistance of cancer cells","volume":"30","author":"Sun","year":"2023","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib241","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","article-title":"Metabolic reprogramming and epigenetic modifications on the path to cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.critrevonc.2026.105278_bib242","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-biochem-062917-012415","article-title":"The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair","volume":"87","author":"Syed","year":"2018","journal-title":"Annu Rev. Biochem"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib243","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.388","article-title":"Double-strand DNA break repair: molecular mechanisms and therapeutic targets","volume":"4","author":"Tan","year":"2023","journal-title":"MedComm"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib244","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib245","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1038\/s41467-023-42850-x","article-title":"Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib246","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S1470-2045(20)30431-9","article-title":"BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?","volume":"21","author":"Telli","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib247","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41523-023-00568-5","article-title":"Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1\/2 wildtype triple-negative breast cancer","volume":"9","author":"Teo","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib248","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2018.05.013","article-title":"Cytosolic DNA sensing in organismal tumor control","volume":"34","author":"Vanpouille-Box","year":"2018","journal-title":"Cancer Cell"},{"issue":"7419","key":"10.1016\/j.critrevonc.2026.105278_bib249","article-title":"Integrated genomic analyses of ovarian carcinoma (vol 474, pg 609, 2011)","volume":"490","author":"Vockley","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib250","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/s41467-020-15912-7","article-title":"Mutational signatures are jointly shaped by DNA damage and repair","volume":"11","author":"Volkova","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105278_bib251","first-page":"1","article-title":"Sustained clinical response to Olaparib in a patient with metastatic pancreatic cancer and somatic ATM-Mutation R2034Ter: a case report","author":"Vornhulz","year":"2025","journal-title":"Oncol. Res Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib252","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/1078-0432.CCR-22-1553","article-title":"Preclinical and clinical trial results using talazoparib and low-dose chemotherapy","volume":"29","author":"Wainberg","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105278_bib253","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib254","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105278_bib255","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1016\/j.cell.2024.07.058","article-title":"Harnessing immune cells to leverage PARP inhibitors","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105278_bib256","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.actbio.2022.12.021","article-title":"Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity","volume":"157","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2026.105278_bib257","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.762989","article-title":"PARP inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib258","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/j.1460-2075.1995.tb07180.x","article-title":"Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle","volume":"14","author":"Watanabe","year":"1995","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib259","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41388-024-03207-w","article-title":"Enhancing low-dose radiotherapy efficacy with PARP inhibitors via FBL-mediated oxidative stress response in colorectal cancer","volume":"44","author":"Wen","year":"2025","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105278_bib261","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib262","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060642","article-title":"DNA replication stress and chromosomal instability: dangerous liaisons","volume":"11","author":"Wilhelm","year":"2020","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib263","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41416-021-01560-1","article-title":"Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response","volume":"125","author":"Willis","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib264","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib265","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib266","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1535-7163.MCT-20-0848","article-title":"PARP and CDK4\/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105278_bib267","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.ygyno.2024.07.110","article-title":"Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial","volume":"190","author":"Wu","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib268","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial","volume":"30","author":"Wu","year":"2024","journal-title":"Nat. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib269","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib monotherapy for patients with germline BRCA1\/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study","volume":"28","author":"Wu","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib270","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial(","volume":"32","author":"Wu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105278_bib271","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009032","article-title":"PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer","volume":"12","author":"Xia","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib272","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gutjnl-2024-332782","article-title":"TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality","volume":"74","author":"Xiao","year":"2025","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105278_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109978","article-title":"CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer","volume":"27","author":"Xu","year":"2024","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105278_bib274","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1158\/1541-7786.MCR-20-0791","article-title":"CHK2 inhibition provides a strategy to suppress hematologic toxicity from PARP inhibitors","volume":"19","author":"Xu","year":"2021","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105278_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101151","article-title":"CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer","volume":"77","author":"Xue","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib276","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105278_bib277","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121920","article-title":"A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer","volume":"292","author":"Yao","year":"2023","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105278_bib278","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/2159-8290.CD-NB2022-0064","article-title":"Alternating WEE1 CPARP blockade: high potential","volume":"12","author":"Yap","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib279","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib280","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41467-024-46283-y","article-title":"GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer","volume":"15","author":"Ye","year":"2024","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105278_bib281","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-22-3646","article-title":"Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors","volume":"83","author":"Yu","year":"2023","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105278_bib282","article-title":"Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-mediated MLH1 intron retention","volume":"11","author":"Yue","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"6486","key":"10.1016\/j.critrevonc.2026.105278_bib283","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib284","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Poltheta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105278_bib285","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.2025028560","article-title":"Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer","volume":"146","author":"Zeisig","year":"2025","journal-title":"Blood"},{"issue":"7779","key":"10.1016\/j.critrevonc.2026.105278_bib286","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib287","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105278_bib288","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2422720122","article-title":"ATM priming and end resection-coupled phosphorylation of MRE11 is important for fork protection and replication restart","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105278_bib289","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0092-8674(00)80936-8","article-title":"BRCA1, BRCA2, and DNA damage response: collision or collusion?","volume":"92","author":"Zhang","year":"1998","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib290","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12951-025-03516-6","article-title":"SIRT5-modified human umbilical cord mesenchymal stem cells loaded with antioxidant polydopamine nanozyme enhance parpi resistance in ovarian cancer via fatty acid metabolism reprogramming","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105278_bib291","article-title":"Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib292","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41419-022-04982-8","article-title":"Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib293","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114180","article-title":"Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105278_bib294","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2024.06.012","article-title":"Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment","volume":"371","author":"Zheng","year":"2024","journal-title":"J. Control Release"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105278_bib295","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105278_bib296","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tim.2021.01.002","article-title":"When PARPs meet antiviral innate immunity","volume":"29","author":"Zhu","year":"2021","journal-title":"Trends Microbiol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib297","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105278_bib298","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105278_bib299","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41589-022-01240-y","article-title":"SIRT1 deacetylates WEE1 and sensitizes cancer cells to WEE1 inhibition","volume":"19","author":"Zhu","year":"2023","journal-title":"Nat. Chem. Biol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:37:11Z","timestamp":1778481431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":299,"alternative-id":["S1040842826001654"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105278","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing synergy: Innovative combinations to overcome PARP inhibitor resistance in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105278"}}